Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that managed care presents significant hurdles for Aventis's Ketek in the areas of product differentiation and formulary inclusion. According to the new primary research report entitled Antibiotics: Impact of Major Patent Expiries and New Drug Entrants, 55% of HMO pharmacy directors perceive Ketek as a "me-too" macrolide. This conflicts with the 50% of primary care physicians (PCPs) who indicate that they would prescribe Ketek because of its unique resistance profile.

"More than 70% of HMO pharmacy directors surveyed predict that they will impose significant restrictions on Ketek's use -- of those, 20% predict Ketek will not be placed on formulary," said John Lebbos, M.D., analyst at Decision Resources.

The report also finds that there is a notable disparity between PCPs and HMO directors in their perception of the newer fluoroquinolones. PCPs rank Johnson & Johnson's Levaquin as the preferred first-choice therapy for community-acquired pneumonia and chronic bronchitis in contrast to HMO directors, who consider the less expensive amoxicillin as their first choice.

"PCPs perceive the benefits of the new quinolones, Bristol-Myers Squibb's Tequin and Bayer's Avelox, in efficacy and compliance while only one-third of HMO pharmacy directors cite that these agents have a clinical advantage (namely broader spectrum) over Levaquin," continued Dr. Lebbos.

Antibiotics: Impact of Major Patent Expiries and New Drug Entrants is based on a survey of 20 HMO pharmacy directors and 70 PCPs. Participants in all groups were located throughout the United States. Their responses were compared to assess similarities and differences in clinical, economic, and scientific factors.

About PhysicianForum

PhysicianForum is a new primary research service from Decision Resources. The service offers access to high-volume prescribing PCPs, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and implications for the pharmaceutical market.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,

Bristol-Myers Squibb, Novartis/Idenix, and Gilead Will All Launch New Offerings in the Hepatitis B Drug Market

View Now